Loading...
Market
Will at least 10 million doses of Moderna's updated KP.2 variant vaccine be administered in the US by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Adoption rate can be verified through public health reports and vaccination statistics
Story
Health Canada Approves Moderna's Updated COVID-19 Vaccine Targeting KP.2 Variant for Ages Six Months and Older
Sep 17, 2024, 03:06 PM
Health Canada has approved Moderna's updated COVID-19 vaccine targeting the KP.2 variant of SARS-CoV-2 for ages six months and older. This approval follows the FDA's authorization of three updated vaccines, including Pfizer-BioNTech, Moderna, and Novavax, which received FDA authorization in August. The Moderna vaccine, known as Spikevax, is expected to be available soon at major retailers such as RiteAid, Costco, CVS, Walgreens, and Walmart. Studies indicate that Novavax, a protein-based vaccine, has fewer side effects compared to mRNA vaccines like Moderna. Novavax reduces viral load by 600x, while Moderna reduces it by 100x.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 5 million • 25%
5 million to 10 million • 25%
10 million to 15 million • 25%
More than 15 million • 25%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%